Why India's High TB Burden Demands Urgent Transparency

The persistent India TB burden remains a critical challenge for clinicians and public health policymakers alike. Although mortality fell by 38 percent since 2015, severe structural hurdles continue to hinder eradication efforts. Recently, public health network Jan Swasthya Abhiyan India raised grave concerns regarding official disease estimates and programme accountability. Consequently, clinicians must examine how surveillance discrepancies and medication stockouts affect grassroots tuberculosis management.
Evaluating the Discrepancies in the India TB Burden
According to recent WHO data, 10.6 million individuals developed active tuberculosis globally during 2025. Furthermore, India still accounts for approximately one-fourth of global cases and 23 percent of worldwide tuberculosis fatalities. However, international agencies recently placed India's latest incidence figures under review pending sentinel surveillance validation. In addition, advocates emphasize that the Central TB Division has stalled annual reporting beyond the 2024 edition. Therefore, independent researchers face significant difficulties when attempting to evaluate district-level trends across individual states.
Impact of Medication Shortages on Tuberculosis Care
Besides surveillance gaps, healthcare facilities have experienced substantial disruptions in the procurement of essential anti-TB medications. Specifically, central supplies of intensive-phase fixed-dose combinations fell by 56.5 percent in 2023 compared to 2022. Meanwhile, supplies designated for continuation-phase regimens dropped by 23 percent during the same reporting period. Official audits also identified that expired anti-TB medicines worth over 40 crore rupees accumulated across five regional depots. Consequently, intermittent medication access forces patients to interrupt therapy, dramatically increasing the risk of secondary drug resistance.
Strengthening Accountability Within the National Programme
To protect patient outcomes, health advocates now demand transparent, real-time monitoring across all treatment centres. Furthermore, expert networks recommend that authorities publish monthly disclosures covering stock levels, buffer inventories, and emergency procurement. Clinicians also require accurate district-level surveillance data to allocate diagnostic resources and prevent disease transmission effectively. Ultimately, bridging these administrative gaps will ensure that therapeutic gains translate into genuine community-wide disease elimination.
Frequently Asked Questions
Q1: Why is the India TB burden receiving renewed scrutiny despite declining mortality?
Although tuberculosis mortality declined by 38 percent since 2015, India still accounts for 25 percent of global cases. Moreover, delays in publishing local surveillance reports prevent independent validation of incidence numbers.
Q2: How do anti-TB medication shortages impact clinical management?
Supply chain disruptions interrupt standard intensive and continuation regimens. Consequently, treatment interruptions increase treatment failure rates and drive the development of drug-resistant tuberculosis strains.
Q3: What reforms are public health advocates demanding for the National Tuberculosis Elimination Programme?
Advocacy groups are urging authorities to establish real-time drug tracking, maintain adequate facility buffer stocks, and publish annual district-level epidemiologic performance data.
References
- Patient group flags high TB burden despite mortality decline, seeks transparencyin reporting - ETHealthworld
- Global tuberculosis report 2026 - World Health Organization (WHO)
- India Makes Major Strides Towards TB Elimination: 38% Decline in TB Mortality, 94% Treatment Success Rate - Press Information Bureau, Delhi





